Market News AIOpen the app

Aldeyra plans to challenge the FDA's rejection, causing its stock to jump 13.79%.

RulesRead the original at Benzinga
Neutral

Aldeyra plans to challenge the FDA’s rejection, but the agency cited too little reliable evidence that reproxalap works. The request has not changed that decision, so the story does not change Aldeyra’s outlook.

ALDX · Aldeyra Therapeutics, Inc.

AI read · Neutral

The AI's read

The request could give Aldeyra another chance to challenge the FDA’s decision, but it adds no proof that the treatment works. The FDA said controlled studies did not provide enough evidence and asked Aldeyra to examine why some trials failed. It did not recommend more trials, but no new study result or decision reversal is reported.

Get alerts for ALDX

Follow Aldeyra Therapeutics, Inc. (ALDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ALDX
Free on the App Store and Google Play, or on the web.